Compass Therapeutics, Inc.(CMPX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Compass Therapeutics, Inc. (CMPX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CMPX at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,375 of 2,739 stocks — the bottom half of the AI-ranked universe. CMPX scores in the top quartile across institutional flow (79.2). Areas of concern include balance sheet strength (3.8) and earnings quality (27.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Compass Therapeutics, Inc. reports net income of $-25.2M, free cash flow of $-14.9M. Top institutional holders of CMPX by reported 13-F value include TANG CAPITAL MANAGEMENT, ORBIMED ADVISORS, SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. CMPX trades on the Nasdaq exchange and files with the SEC under CIK 1738021. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CMPX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Compass Therapeutics, Inc. directly from SEC EDGAR.